Neutral impactOrders & Deals

PE majors eye Orbicular Pharma stake, valuation seen up to $1.5 bn

Mint 2 hrs ago·15 Sept 2026, 12:00 am

Private equity firms such as Warburg Pincus and CVC Capital Partners have evinced interest in Orbicular Pharma as the specialty pharma firm explores a stake sale in a deal that will likely value the company up to $1.5 billion.

Key takeaways

  • Category: Orders & Deals.

Why it matters

A routine update. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at Mint.

More Company news

More news

Latest headlines

More news

Aggregated from third-party sources for research. Sentiment & impact are AI-generated, indicative, not advice.